& Weinstock-Guttman, B
Possible adverse effects may include: Injection site reactions : Redness, swelling, irritation, or discomfort Gastrointestinal symptoms : Nausea, vomiting, stomach cramps, or diarrhea Headaches or dizziness Allergic reactions : Rash, itching, shortness of breath, or facial swelling (rare) Increased heart rate or anxiety (typically temporary from B-vitamins) Fatigue or weakness if used improperly Elevated liver enzymes when taken in excess particularly with methionine or choline Insomnia if taken late in the day due to increased energy levels Who should avoid or use caution
1 rating rating ratings 0 rating rating ratings 0 rating rating ratings 0 rating rating ratings 0 rating rating ratings Record the pronunciation of this word in your own voice and play it to listen to how you have pronounced it
The confidence in estimates for comparisons between tirzepatide and semaglutide was high to moderate, except for comparisons vs semaglutide 2.0 mg, where the confidence was low (ESM Table 12)
FDA Safety Announcement: Soliqua FDA Safety Label Change and Revised Drug Label Trulicity (active ingredient: dulaglutide) subcutaneous injection Initial FDA Approval: 2014 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting